Business
Everest Medicines Announces Updated Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of Primary Membranous Nephropathy
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced updated positive results in the ongoing Phase 1b/2a clinical trial for the treatment of primary membranous nephropathy (pMN) with EVER001 (previously known as XNW1011), a next-generation covalent reversible Bruton's tyrosine kinase (BTK) inhibitor with potentially best-in-class c
About this update from Everest Medicines Ltd.
[{"type":"list","items":[{"val":[{"type":"text","content":"As of March 21st, 2025, longer follow-up data was collected from the ongoing Ph1b/2a study of EVER001: in Cohort 1, 11 patients completed 52 weeks of follow-up. In Cohort 2, 7 patients completed 52 weeks of follow-up.","length":217,"tagName":"p"}]},{"val":[{"type":"text","content":"The updated data showed that EVER001 was well-tolerated and efficacious in patients with pMN. These results support the potential of EVER001 as a treatment for proteinuric autoimmune glomerular diseases.","length":203,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Compared to baseline, the geometirc least square mean of anti-PLA2R antibody levels decreased by 62.2% in Cohort 1 and 87.3% in Cohort 2 at week 12. The reductions in both cohorts reached more than 93% at week 24; the reductions in both cohorts were sustained through Week 52.","length":286,"tagName":"p"}]},{"val":[{"type":"text","content":"Geometric LS mean of 24hr proteinuria levels in cohorts 1 and 2 decreased by 57.0% and 67.6% at Week 24, respectively; and further deepened to 76.7% and 80.6% at Week 36, respectively; the reductions in both cohorts were sustained through Week 52.","length":252,"tagName":"p"}]},{"val":[{"type":"text","content":"Consistent with prior results, EVER001 was generally safe and well tolerated. No clinically significant adverse events commonly associated with BTK inhibitors were observed.","length":178,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":716,"olType":false}]}],"tagName":"ul","bulletedList":true,"length":1136,"olType":false},{"type":"text","content":"SHANGHAI, July 2, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced updated positive results in the ongoing Phase 1b/2a clinical trial for the treatment of primary membranous nephropathy (pMN) with EVER001 (previously known as XNW1011), a next-generation covalent reversible Bruton's tyrosine kinase (BTK) inhibitor with potentially best-in-class characteristics for the treatment of autoimmune renal diseases. Compared to covalent irreversible BTK inhibitors, EVER001 offers improved selectivity while maintai...